soul trial oral semaglutide cardiovascular outcomes nejm 2025 results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Oral Semaglutide Reduces Cardiovascular Events

Butz and his entire staff made the experience seamless from start to finish

Evening timing is ideal when: You train after office hours Morning routines feel rushed You prefer daily supplementation with dinner If taken before bed without training, results may not feel as prominent

The bottom line: When in doubt, dont use it

A review of the efficacy of the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet in managing gastrointestinal symptoms related to cancer treatment

At week 52, Zepbound resulted in a significant reduction in the apnea-hypopnea index in individuals who were and were not receiving PAP therapy

That window lines up peak plasma levels with active fat burning